Methods for treating b cell lymphoma using CD80-specific antibodies

1. A method of treating B cell lymphoma comprising administering a therapeutically effective amount of an anti-CD80 antibody, wherein said antibody binds the same epitope as an anti-CD80 antibody selected from the group consisting of 7C10, which has the variable region sequences shown in FIGS. 8 a and 8 b (amino acid sequences of SEQ ID NOs. 1-2 and 3-4 respectively); 7B6, which has the variable region sequences shown in FIGS. 9 a and 9 b (amino acid sequences of SEQ ID NOs. 5-6 and 7-3 respectively); and 16C10, which has the variable region sequences shown in FIGS. 10 a and 10 b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12 respectively).

2. The method of claim 1 wherein said anti-CD80 antibody binds the same epitope as an anti-CD80 antibody selected from the group consisting of 16C10, 7C10, 20C9 and 7B6.

3. A method of treating B cell lymphoma comprising administering a therapeutically effective amount of an anti-CD80 antibody, wherein said antibody binds the same epitope as an anti-CD80 antibody selected from the group consisting of 7C10, which has the variable region sequences shown in FIGS. 8 a and 8 b (amino acid sequences of SEQ ID NOs. 1-2 and 3-4 respectively); 7B6, which has the variable region sequences shown in FIGS. 9 a and 9 b (amino acid sequences of SEQ ID NOs. 5-6 and 7-3 respectively); and 16C10, which has the variable region sequences shown in FIGS. 10 a and 10 b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12 respectively),

wherein said antibody is a non-depleting antibody.

4. A method of treating B cell lymphoma comprising administering a therapeutically effective amount of an anti-CD80 antibody, wherein said antibody is a primatized ® antibody having the variable region sequences of an anti-CD80 antibody selected from the group consisting of 7C10, which has the variable region sequences shown in in FIGS. 8 a and 8 b (amino acid sequences of SEQ ID NOs. 1-2 and 3-4 respectively); 7B6, which has the variable region sequences shown in FIGS. 9 a and 9 b (amino acid sequences of SEQ ID NOs. 5-6 and 7-8, respectively); and 16C10, which has the variable region sequences shown in FIGS. 10 a and 10 b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12 respectively).

5. The method of claim 4 where the antibody is a primatized® antibody having the variable region sequences of antibody 16C10 shown in FIGS. 10 a and 10 b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12, respectively).